Chemotherapy only N = 38 | Cetuximab N = 38 | Bevacizumab N = 106 | Total N = 182 | |
---|---|---|---|---|
Regimen used in 1st line therapy, n (%) | ||||
Oxaliplatin based | 5 (13%) | 4 (11%) | 54 (51%) | 63 (35%) |
Irinotecan based | 21 (55%) | 28 (74%) | 40 (38%) | 89 (49%) |
Neither Oxaliplatin nor Irinotecan based | 12 (32%) | 6 (16%) | 12 (11%) | 30 (16%) |
Regimen used in 2nd line therapy, n (%) | ||||
5-FU | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 1 (0.5%) |
5-FU / AMG 706 / Irinotecan / Leucovorin | 1 (2.6%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) |
5-FU / Gamma Interferon / Irinotecan / Leucovorin | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 1 (0.5%) |
5-FU / Gamma Interferon / Leucovorin | 2 (5.3%) | 0 (0.0%) | 0 (0.0%) | 2 (1.1%) |
5-FU / Interferon / Leucovorin | 2 (5.3%) | 0 (0.0%) | 0 (0.0%) | 2 (1.1%) |
5-FU / Irinotecan / Leucovorin | 6 (15.8%) | 13 (34.2%) | 29 (27.4%) | 48 (26.4%) |
5-FU / Irinotecan / Leucovorin / Oxaliplatin | 0 (0.0%) | 0 (0.0%) | 5 (4.7%) | 5 (2.7%) |
5-FU / Irinotecan / Leucovorin / Oxaliplatin / Capecitabine | 0 (0.0%) | 0 (0.0%) | 2 (1.9%) | 2 (1.1%) |
5-FU / Irinotecan / Leucovorin / Capecitabine | 2 (5.3%) | 0 (0.0%) | 4 (3.8%) | 6 (3.3%) |
5-FU / Leucovorin | 2 (5.3%) | 1 (2.6%) | 3 (2.8%) | 6 (3.3%) |
5-FU / Leucovorin / Oxaliplatin | 3 (7.9%) | 3 (7.9%) | 38 (35.8%) | 44 (24.2%) |
5-FU / Leucovorin / Oxaliplatin / Capecitabine | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 1 (0.5%) |
Bevacizumab Only | 0 (0.0%) | 0 (0.0%) | 2 (1.9%) | 2 (1.1%) |
Cetuximab Only | 0 (0.0%) | 4 (10.5%) | 0 (0.0%) | 4 (2.2%) |
Floxuridine / Irinotecan | 1 (2.6%) | 0 (0.0%) | 0 (0.0%) | 1 (0.5%) |
Irinotecan | 11 (28.9%) | 13 (34.2%) | 3 (2.8%) | 27 (14.8%) |
Irinotecan / Oxaliplatin / Capecitabine | 0 (0.0%) | 0 (0.0%) | 1 (0.9%) | 1 (0.5%) |
Irinotecan / Capecitabine | 0 (0.0%) | 2 (5.3%) | 3 (2.8%) | 5 (2.7%) |
Oxaliplatin / Capecitabine | 2 (5.3%) | 1 (2.6%) | 7 (6.6%) | 10 (5.5%) |
Capecitabine | 6 (15.8%) | 1 (2.6%) | 6 (5.7%) | 13 (7.1%) |